Radiopharm Theranostics Ltd (RADX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 146.79 is considered Overvalued compared with the five-year average of -1.06. The fair price of Radiopharm Theranostics Ltd (RADX) is between 0.92 to 4.73 according to relative valuation method. Compared to the current price of 4.95 USD , Radiopharm Theranostics Ltd By Overvalued By 4.66%.

Relative Value

Fair Zone

0.92-4.73

Current Price：4.95

4.66%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Radiopharm Theranostics Ltd (RADX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Radiopharm Theranostics Ltd (RADX) has a current Price-to-Book (P/B) ratio of 407.18. Compared to its 3-year average P/B ratio of 334.79, the current P/B ratio is approximately 21.62% higher. Relative to its 5-year average P/B ratio of 334.79, the current P/B ratio is about 21.62% higher. Radiopharm Theranostics Ltd (RADX) has a Forward Free Cash Flow (FCF) yield of approximately -41.36%. Compared to its 3-year average FCF yield of -55.70%, the current FCF yield is approximately -25.75% lower. Relative to its 5-year average FCF yield of -55.70%, the current FCF yield is about -25.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RADX competitors is 53.68, providing a benchmark for relative valuation. Radiopharm Theranostics Ltd Corp (RADX.O) exhibits a P/S ratio of 146.79, which is 173.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RADX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RADX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RADX currently overvalued or undervalued?

Radiopharm Theranostics Ltd (RADX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 146.79 is considered Overvalued compared with the five-year average of -1.06. The fair price of Radiopharm Theranostics Ltd (RADX) is between 0.92 to 4.73 according to relative valuation method. Compared to the current price of 4.95 USD, Radiopharm Theranostics Ltd is Overvalued By 4.66%.

What is Radiopharm Theranostics Ltd (RADX) fair value?

RADX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Radiopharm Theranostics Ltd (RADX) is between 0.92 to 4.73 according to relative valuation method.

How does RADX's valuation metrics compare to the industry average?

The average P/S ratio for RADX's competitors is 53.68, providing a benchmark for relative valuation. Radiopharm Theranostics Ltd Corp (RADX) exhibits a P/S ratio of 146.79, which is 173.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Radiopharm Theranostics Ltd (RADX) as of Mar 03 2026?

As of Mar 03 2026, Radiopharm Theranostics Ltd (RADX) has a P/B ratio of 407.18. This indicates that the market values RADX at 407.18 times its book value.

What is the current FCF Yield for Radiopharm Theranostics Ltd (RADX) as of Mar 03 2026?

As of Mar 03 2026, Radiopharm Theranostics Ltd (RADX) has a FCF Yield of -41.36%. This means that for every dollar of Radiopharm Theranostics Ltd's market capitalization, the company generates -41.36 cents in free cash flow.

What is the current Forward P/E ratio for Radiopharm Theranostics Ltd (RADX) as of Mar 03 2026?

As of Mar 03 2026, Radiopharm Theranostics Ltd (RADX) has a Forward P/E ratio of -2.35. This means the market is willing to pay $-2.35 for every dollar of Radiopharm Theranostics Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Radiopharm Theranostics Ltd (RADX) as of Mar 03 2026?

As of Mar 03 2026, Radiopharm Theranostics Ltd (RADX) has a Forward P/S ratio of 146.79. This means the market is valuing RADX at $146.79 for every dollar of expected revenue over the next 12 months.

RADX Valuation